Grufity logo
Grufity logo

Latest Soleus Capital Management, L.P. Stock Portfolio

$2.47Billion | No. of Holdings #93

Soleus Capital Management, L.P. Performance

2026 Q1-2.29%
YTD-2.29%
2025+25.13%

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $2.5 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Soleus Capital Management, L.P. are KRYS, CELC, TGTX. The fund has invested 12.1% of it's portfolio in KRYSTAL BIOTECH INC and 5.9% of portfolio in CELCUITY INC . <br><br> The fund managers got completely rid off AMICUS THERAPEUTICS INC (FOLD), GSK PLC (GSK) and RAPT THERAPEUTICS INC (RAPT) stocks. They significantly reduced their stock positions in ORUKA THERAPEUTICS INC, RIGEL PHARMACEUTICALS INC (RIGL) and ANAPTYSBIO INC (ANAB). Soleus Capital Management, L.P. opened new stock positions in INDIVIOR PHARMACEUTICALS INC, PROGYNY INC (PGNY) and MERCK & CO INC (MRK). The fund showed a lot of confidence in some stocks as they added substantially to TANGO THERAPEUTICS INC (TNGX), VERACYTE INC (VCYT) and NATERA INC (NTRA).
Soleus Capital Management, L.P. Equity Portfolio Value
Last Reported on: 14 May, 2026
$2.47Billion
  as of May 14, 2026

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of -2.29% in the last quarter. In trailing 12 months, it's portfolio return was 37.68%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
indivior pharmaceuticals inc38,831,500
progyny inc 35,097,700
merck & co inc 24,418,900
icon plc 21,246,700
context therapeutics inc 18,243,400
vir biotechnology inc 17,937,900
xenon pharmaceuticals inc 16,979,800
travere therapeutics inc 16,221,700
New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker% Inc.
tango therapeutics inc 4,400
veracyte inc 3,099
natera inc 495
inhibrx biosciences inc 424
urogen pharma ltd 384
insulet corp 275
vericel corp 233
united therapeutics corp del211
Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker% Reduced
oruka therapeutics inc -97.37
rigel pharmaceuticals inc -96.67
anaptysbio inc -95.56
tyra biosciences inc -92.00
cogent biosciences inc -91.67
zymeworks inc -90.00
dexcom inc -89.21
argenx se -88.97
Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker$ Sold
amicus therapeutics inc-74,151,700
erasca inc-8,043,240
rapt therapeutics inc-25,876,700
calcimedica inc-4,506,930
capricor therapeutics inc-18,654,800
gsk plc-31,336,600
moonlake immunotherapeutics-5,272,000
fractyl health inc-880,000
Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 89.8% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare89.8
Others9.8

Market Cap. Distribution

Soleus Capital Management, L.P. has about 16.6% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • SMALL-CAP
  • LARGE-CAP
  • UNALLOCATED
  • MICRO-CAP
Category%
MID-CAP41.6
SMALL-CAP27.2
LARGE-CAP16.6
UNALLOCATED9.8
MICRO-CAP3.8

Stocks belong to which Index?

About 62.2% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200056.1
Others37.8
S&P 5006.1
Top 5 Winners (%)%
enliven therapeutics inc
94.7 %
TNGX
tango therapeutics inc
41.8 %
TWST
twist bioscience corp
41.3 %
CCCC
c4 therapeutics inc
37.7 %
cg oncology inc
35.2 %
Top 5 Winners ($)$
TWST
twist bioscience corp
24.4 M
CELC
celcuity inc
22.3 M
enliven therapeutics inc
14.9 M
UTHR
united therapeutics corp del
13.1 M
KRYS
krystal biotech inc
12.3 M
Top 5 Losers (%)%
beta bionics inc
-61.8 %
ORGO
organogenesis hldgs inc
-54.1 %
JSPR
jasper therapeutics inc
-48.4 %
ADGI
invivyd inc
-47.4 %
QNRX
quoin pharmaceuticals ltd
-44.4 %
Top 5 Losers ($)$
beta bionics inc
-70.4 M
ORGO
organogenesis hldgs inc
-28.2 M
PODD
insulet corp
-26.5 M
NVCR
novocure ltd
-19.3 M
INSP
inspire med sys inc
-17.8 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 93 stocks in it's portfolio. About 50.3% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. TWST was the most profitable stock for Soleus Capital Management, L.P. last quarter.

$2.47BTotal Value
119Positions
14 May, 2026Last Reported
Current holdings of Current Stock Holdings of Soleus Capital Management, L.P., last reported on 14 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ARGX
Argenx Se

Argenx Se

ARGX
Soleus Capital Management, L.P.'s holding in Argenx Se over time
0.1%3,500
$2.56M
0.1%
decreased 88.97 percentreduced
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Soleus Capital Management, L.P.'s holding in Belite Bio Inc over time
0%0.00
$0.00
0%
decreased 100 percentsold off